OR WAIT null SECS
© 2024 MJH Life Sciences and Pharmaceutical Technology. All rights reserved.
© 2024 MJH Life Sciences™ and Pharmaceutical Technology. All rights reserved.
May 02, 2012
A technical forum featuring Tim Freeman of Freeman Technology and Carl Levoguer of Malvern Instruments.
Manufacturers seek clear path to develop safe-use approaches for more risky OTC therapies.
It's better to catch costly mistakes in the laboratory before they reach the accounting department.
Equipment design and cleaning procedures both play a role in thorough sterilization and cleaning.
Targeted polymeric nanoparticles are an important vehicle for controlling and targeting dosing of chemotherapeutic agents.
Industry experts working with extended-release injectables discuss challenges and solutions to formulating and manufacturing these complex products.
The author outlines the scientific aspects of forced degradation studies that should be considered in relation to ANDA submissions.
From The Editor
Apple's experience with manufacturing facilities in China present opportunity for future best practice.
Service providers must focus on delivering a superior customer experience.
How niche strategies can offer mainstream potential for biopharmaceutical companies.
In the Spotlight
New product reviews for May 2012.
The author discusses potential opportunities to improve the patient experience through formulation and delivery device technologies.
In the Field
Poland's government aims to make the Eastern European country a biotech powerhouse.
Advances in palladium-catalyzed hydrogenation, visible-light photocatalysis, and chemocatalyisis for heterocycles are some recent developments.
Industry, the public sector, and individuals can play an important role in creating solutions.
Q&A with David Elder of Strategic Compliance Consulting, PAREXEL International on responding to a 483 within 15 days. Elder is a former senior official with FDA.
May 01, 2012